StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Equities researchers at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued on Thursday. The firm set a “hold” rating on the medical research company’s stock.

CTSO has been the subject of a number of other reports. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Monday, January 13th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.02 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The company has a fifty day moving average of $0.96 and a two-hundred day moving average of $1.04. The stock has a market capitalization of $55.77 million, a PE ratio of -2.83 and a beta of 0.61. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.59.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. During the same quarter in the prior year, the company posted ($0.21) earnings per share. As a group, research analysts forecast that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently modified their holdings of the business. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents in the third quarter valued at about $51,000. Sargent Investment Group LLC grew its holdings in shares of Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after purchasing an additional 192,747 shares during the period. Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Skylands Capital LLC grew its holdings in shares of Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Cytosorbents in the fourth quarter valued at about $99,000. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.